Overview

Amiloride Clinical Trial In Optic Neuritis

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Optic neuritis (ON) is a common event in Multiple Sclerosis (MS), and causes significant loss of nerve cells in the eye, resulting in poor vision. Optic neuritis also provides a sensitive way of testing the effectiveness of drugs that may help protect from loss of nerve cells in ON and therefore in MS. The investigators have identified through laboratory and early clinical research in humans that amiloride (a water tablet already in use) may be a drug that can be of benefit in optic neuritis by protecting from loss of nerves cells, ie a neuroprotective drug. The purpose of this study is to assess the efficacy of amiloride as a neuroprotective drug in optic neuritis
Phase:
Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborator:
Multiple Sclerosis Society of Great Britain and Northern Ireland
Treatments:
Amiloride